- Home
- PHUN vs IVVD Comparison
PHUN vs IVVD Comparison
Compare PHUN & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHUN
- IVVD
- Stock Information
- Founded
- PHUN 2009
- IVVD 2020
- Country
- PHUN United States
- IVVD United States
- Employees
- PHUN N/A
- IVVD N/A
- Industry
- PHUN EDP Services
- IVVD Biotechnology: Pharmaceutical Preparations
- Sector
- PHUN Technology
- IVVD Health Care
- Exchange
- PHUN Nasdaq
- IVVD Nasdaq
- Market Cap
- PHUN 64.1M
- IVVD 69.0M
- IPO Year
- PHUN N/A
- IVVD 2021
- Fundamental
- Price
- PHUN $3.11
- IVVD $0.68
- Analyst Decision
- PHUN Buy
- IVVD Strong Buy
- Analyst Count
- PHUN 2
- IVVD 3
- Target Price
- PHUN $7.75
- IVVD $5.85
- AVG Volume (30 Days)
- PHUN 269.3K
- IVVD 1.2M
- Earning Date
- PHUN 08-07-2025
- IVVD 08-13-2025
- Dividend Yield
- PHUN N/A
- IVVD N/A
- EPS Growth
- PHUN N/A
- IVVD N/A
- EPS
- PHUN N/A
- IVVD N/A
- Revenue
- PHUN $2,956,000.00
- IVVD $36,688,000.00
- Revenue This Year
- PHUN $3.01
- IVVD $446.60
- Revenue Next Year
- PHUN $50.72
- IVVD $112.63
- P/E Ratio
- PHUN N/A
- IVVD N/A
- Revenue Growth
- PHUN N/A
- IVVD N/A
- 52 Week Low
- PHUN $2.22
- IVVD $0.35
- 52 Week High
- PHUN $14.60
- IVVD $2.74
- Technical
- Relative Strength Index (RSI)
- PHUN 50.33
- IVVD 40.96
- Support Level
- PHUN $3.16
- IVVD $0.70
- Resistance Level
- PHUN $3.56
- IVVD $0.76
- Average True Range (ATR)
- PHUN 0.16
- IVVD 0.05
- MACD
- PHUN -0.01
- IVVD -0.00
- Stochastic Oscillator
- PHUN 42.62
- IVVD 5.11
About PHUN Phunware Inc.
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States. The company has two reportable segments: Software subscriptions and services; and Advertising. It derives maximum revenue from Software subscriptions and services.
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.